XNAS · Healthcare · Biotechnology
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.
Autoimmune biotech **missed EPS by $0.11** at -$0.73, but IMVT-1402 FcRn inhibitor pipeline progress supports continued clinical development momentum.
AI-generated summary — powered by BigEarnings.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-20 | Q4 2026 | -0.62 | -0.73 | -17.74% | $0 | ❌ Miss | +10.08% | -6.05% | — |
| 2026-02-06 | Q3 2026 | -0.71 | -0.61 | +14.08% | $0 | ✅ Beat | +7.40% | -4.81% | -2.37% |
| 2025-11-10 |
| Q2 2026 |
| -0.72 |
| -0.73 |
| -1.39% |
| $0 |
| ❌ Miss |
| — |
| — |
| — |
| 2025-08-11 | Q1 2026 | -0.68 | -0.71 | -4.41% | $0 | ❌ Miss | -2.39% | +3.39% | +9.76% |
| 2025-02-06 | Q3 2025 | -0.76 | -0.76 | +0.00% | $0 | ➖ Inline | +0.25% | -2.46% | -0.29% |
| 2024-11-07 | Q2 2025 | -0.60 | -0.74 | -23.33% | $0 | ❌ Miss | +2.41% | -6.28% | -4.11% |
| 2024-08-06 | Q1 2025 | -0.53 | -0.60 | -13.21% | $0 | ❌ Miss | -3.12% | +6.97% | +20.72% |
| 2024-05-29 | Q4 2024 | -0.43 | -0.52 | -20.93% | $0 | ❌ Miss | -10.69% | -13.43% | -10.72% |
Showing last 8 quarters.